<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2138">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05133323</url>
  </required_header>
  <id_info>
    <org_study_id>19678A</org_study_id>
    <nct_id>NCT05133323</nct_id>
  </id_info>
  <brief_title>A Study With Lu AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments</brief_title>
  <official_title>Interventional, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of Lu AG09222 for the Prevention of Migraine in Patients With Unsuccessful Prior Preventive Treatments</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lundbeck A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>H. Lundbeck A/S</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Researchers are trying to learn whether a drug called Lu AG09222 can help prevent migraine&#xD;
      headaches for people who have not been helped by other treatments that are used to prevent&#xD;
      migraines.&#xD;
&#xD;
      People who join this trial have tried 2 to 4 other medications to prevent their migraines,&#xD;
      but these medications have not helped them.&#xD;
&#xD;
      When the trial is over, researchers will use this information to find out if the number of&#xD;
      migraine days decreased more for the participants who got either dose of Lu AG09222 than for&#xD;
      the participants who got the placebo.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants will be randomly allocated to one of 3 treatment groups: Lu AG09222 high dose,&#xD;
      Lu AG09222 low dose, or placebo, in a ratio of 2:1:2.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 11, 2021</start_date>
  <completion_date type="Anticipated">February 25, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 28, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in the Number of Monthly Migraine Days (MMDs) at Month 1 (Weeks 1-4)</measure>
    <time_frame>Baseline, Month 1 (Weeks 1-4)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With ≥50% Reduction From Baseline in MMDs</measure>
    <time_frame>Baseline up to Month 1 (Weeks 1-4)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Number of Monthly Headache Days (MHDs) at Month 1 (Weeks 1-4)</measure>
    <time_frame>Baseline, Month 1 (Weeks 1-4)</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">230</enrollment>
  <condition>Migraine</condition>
  <arm_group>
    <arm_group_label>Lu AG09222 High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single high dose of Lu AG09222 by intravenous (IV) infusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lu AG09222 Low Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single low dose of Lu AG09222 by IV infusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive a single dose of placebo matching to Lu AG09222 by IV infusion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lu AG09222</intervention_name>
    <description>Lu AG09222 will be administered per schedule specified in the arm.</description>
    <arm_group_label>Lu AG09222 High Dose</arm_group_label>
    <arm_group_label>Lu AG09222 Low Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo matching to Lu AG09222 will be administered per schedule specified in the arm.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  The participant has a diagnosis of migraine as defined by International Classification&#xD;
             of Headache Disorders Third Edition (ICHD-3) guidelines confirmed at the Screening&#xD;
             Visit.&#xD;
&#xD;
          -  The participant has a history of migraine onset at least 12 months prior to the&#xD;
             Screening Visit.&#xD;
&#xD;
          -  The participant has a migraine onset of ≤50 years of age.&#xD;
&#xD;
          -  The participant has documented evidence of treatment failure in the past 10 years of&#xD;
             at least 2 to 4 (maximum) different migraine preventive medications.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  The participant has been previously dosed with an anti-pituitary adenylate&#xD;
             cyclase-activating polypeptide (anti-PACAP) ligand-targeting antibody.&#xD;
&#xD;
          -  The participant has confounding and clinically significant pain syndromes.&#xD;
&#xD;
          -  The participant has a diagnosis of acute or active temporomandibular disorder.&#xD;
&#xD;
          -  The participant has a history or diagnosis of confounding headaches.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Email contact via H. Lundbeck A/S</last_name>
    <role>Study Director</role>
    <affiliation>H. Lundbeck A/S</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Email contact via H. Lundbeck A/S</last_name>
    <phone>+45 36301311</phone>
    <email>LundbeckClinicalTrials@Lundbeck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Allied Biomedical Research Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33155</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 15, 2021</study_first_submitted>
  <study_first_submitted_qc>November 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 24, 2021</study_first_posted>
  <last_update_submitted>November 15, 2021</last_update_submitted>
  <last_update_submitted_qc>November 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

